Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Irritable Bowel Syndrome (IBS) Health Center

Font Size

IBS Drug Zelnorm Taken Off U.S. Market

FDA: Voluntary Withdrawal Due to Risk of Heart Attack, Stroke, Chest Pain
WebMD Health News
Reviewed by Louise Chang, MD

March 30, 2007 -- A popular drug for irritable bowel syndrome and constipation was pulled from the U.S. market Friday amid new evidence that it raises the risk of heart attacks and strokes.

Novartis, the manufacturer of Zelnorm, confirmed that Food and Drug Administration officials asked for the drug’s withdrawal.

Agency officials said they based their decision on a Swiss government analysis of 29 Zelnorm studies that showed a higher chance of cardiovascular events, such as heart attack, stroke, or severe heart-related chest pain in patients treated with Zelnorm compared with those given a placebo.

The analysis turned up 13 cases of heart attack, stroke, or angina (chest pain related to heart disease) in about 11,600 patients who took the drug. One of the 13 died, the agency said. This was compared with just one nonfatal event in more than 7,000 patients who took the placebo.

John Jenkins, MD, head of the FDA’s Office of New Drugs, described the overall number of dangerous events as “quite small.” But he said the rate of cardiovascular events -- about 10 times higher in patients taking Zelnorm -- raised alerts about the drug.

“Based on our review of the data we believed that the risk vs. benefit profile for Zelnorm was no longer favorable,” Jenkins told reporters on a conference call.

He said patients taking Zelnorm should speak immediately to their doctors.

Special Access to Zelnorm

Though the drug will no longer be widely available, patients who have no other treatment options could still get access to the drug. The FDA said it is likely to allow Novartis to continue selling Zelnorm to patients if their doctors say they have disease that does not respond to any other treatment and if the benefits of treatment with Zelnorm outweigh the risks of serious side effects. Drug access would be done through a special program.

The FDA says it has told Novartis that it's willing to consider limited reintroduction of Zelnorm at a later date if a population of patients can be identified in whom the benefits of the drug outweigh the risks.

Today on WebMD

filling glass of water from faucet
Prevention strategies to try.
stomach ache
From symptoms to treatments.
Causes, symptoms, and treatments.
worried mature woman
Are they related?
IBS Trigger Foods
Supplements for IBS What Works
IBS Symptoms Quiz
digestive health
gluten free diet
digestive myths
what causes diarrhea
man with abdominal pain

WebMD Special Sections